Tempus AI

TEM

Market cap $10B

TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta™, intended for the comprehensive genomi.

Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Tempus AI (NASDAQ:TEM) shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego. “The research that Tempus is presenting at this year's AACR annual meeting underscores the scale and real-world impact of Tempus' multimodal dataset and AI-enabled diagn.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus' secure, AI-enabled physician portal. Because NC.

Tempus AI rides on diagnostics growth, AI-driven data demand, and pricing gains - but persistent losses and valuation questions complicate the buy-or-sell call.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead's oncology pipeline. To date, Gilead has leveraged Tempus' extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16. Tempus' Chief Financial Officer Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am ET. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision me.

Tempus AI's data arm surges with 69.5% Insights growth, $1.1B+ contracts, and AI-driven expansion fueling strong revenue outlook and customer retention gains.